Prostaglandin E2 reverses aberrant production of an inflammatory chemokine by microglia from sandhoff disease model mice through the cAMP-PKA pathway

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Kawashita, Eri ^a,b   Tsuji, Daisuke ^a,c   Toyoshima, Masahiro ^a   Kanno, Yosuke ^b   Matsuno, Hiroyuki ^b   Itoh, Kohji ^a,c  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; CHEMOKINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; SANDHOFF DISEASE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; INFLAMMATION; METABOLISM;

MURINAE; MUS;

ANIMALS; CHEMOKINE CCL3; CHEMOKINES; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DINOPROSTONE; DISEASE MODELS, ANIMAL; INFLAMMATION; MICE; MICROGLIA; SANDHOFF DISEASE; SIGNAL TRANSDUCTION;

EID: 79551511690     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016269     Document Type: Article

References (33)

1. Mahuran DJ (1999) Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim Biophys Acta 1455: 105-138.
2. Gravel RA, Kaback MM, Proia RL, Sandhoff K, Suzuki K, et al. (2001) The Metabolic and Molecular Basis of Inherited Disease: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. 8th edit., Vol.3 3827-3877. McGraw-Hill, New York.
3. Gonza ́lez-Scarano F, Baltuch G (1999) Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 22: 219-240.
4. Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 38: 333-347.
5. Sango K, Yamanaka S, Hoffmann A, Okuda Y, Grinberg A, et al. (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 11: 170-176.
6. Huang JQ, Trasler JM, Igdoura S, Michaud J, Hanal N, et al. (1997) Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 6: 1879-1885.
7. Wada R, Tifft CJ, Proia RL (2000) Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA 97: 10954-10959.
8. Myerowitz R, Lawson D, Mizukami H, Mi Y, Tifft CJ, et al. (2002) Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum Mol Genet 11: 1343-1350.
9. Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, et al. (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126: 974-987.
10. Tsuji D, Kuroki A, Ishibashi Y, Itakura T, Kuwahara J, et al. (2005) Specific induction of macrophage inflammatory protein-1alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates. J Neurochem 92: 1497-1507.
11. Kawashita E, Tsuji D, Kawashima N, Nakayama K, Matsuno H, et al. (2009) Abnormal production of macrophage inflammatory protein-1alpha by microglial cell lines derived from neonatal brains of Sandhoff disease model mice. J Neurochem 109: 1215-1224.
12. Wu YP, Proia RL (2004) Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc Natl Acad Sci USA 101: 8425-8430.
13. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB (1986) Arachidonic acid metabolism. Annu Rev Biochem 55: 69-102.
14. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP (2002) Prostaglandins as modulators of immunity. Trends Immunol 23: 144-150.
15. Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282: 11613-11617.
16. Jin J, Shie FS, Liu J, Wang Y, Davis J, et al. (2007) Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation 4: 2.
17. Liang X, Wang Q, Shi J, Lokteva L, Breyer RM, et al. (2008) The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 64: 304-314.
18. Caggiano AO, Kraig RP (1999) Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin- 1beta production. J Neurochem 72: 565-575.
19. McCullough L, Wu L, Haughey N, Liang X, Hand T, et al. (2004) Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24: 257-268.
20. Li J, Liang X, Wang Q, Breyer RM, McCullough L, et al. (2008) Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett 438: 210-215.
21. Takayama K, Garci ́a-Cardena G, Sukhova GK, Comander J, Gimbrone MA, Jr., et al. (2002) Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277: 44147-44154.
22. Jing H, Vassiliou E, Ganea D (2003) Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. J Leukoc Biol 74: 868-879.
23. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, et al. (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396: 474-477.
24. Bos JL (2006) Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 31: 680-686.
25. Enserink JM, Christensen AE, de Rooij J, van Triest M, Schwede F, et al. (2002) A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol 4: 901-906.
26. Christensen AE, Selheim F, de Rooij J, Dremier S, Schwede F, et al. (2003) cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J Biol Chem 278: 35394-35402.
27. Jing H, Yen JH, Ganea D (2004) A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2. J Biol Chem 279: 55176-55186.
28. Jeyakumar M, Butters TD, Cortina-Borja M, Hunnam V, Proia RL, et al. (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A 96: 6388-6393.
29. Wortmann SB, Lefeber DJ, Dekomien G, Willemsen MA, Wevers RA, et al. (2009) Substrate deprivation therapy in juvenile Sandhoff disease. J Inherit Metab Dis. In press.
30. Norflus F, Tifft CJ, McDonald MP, Goldstein G, Crawley JN, et al. (1998) Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J Clin Invest 101: 1881-1888.
31. Wada R, Tifft CJ, Proia RL (2000) Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci U S A 97: 10954-10959.
32. Lee JP, Jeyakumar M, Gonzalez R, Takahashi H, Lee PJ, et al. (2007) Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 13: 439-447.
33. Matsuoka K, Tsuji D, Aikawa S, Matsuzawa F, Sakuraba H, et al. (2010) Introduction of an N-glycan sequon into HEXA enhances human betahexosaminidase cellular uptake in a model of Sandhoff disease. Mol Ther 18: 1519-1526.